CD274 and hepatocellular carcinoma: Atezolizumab (ICI, anti-PD-L1 antibody) 1200 mg plus bevacizumab (anti-VEGF antibody) 15 mg/kg once every 21 days were administered to 104 patients with advanced HCC, while 59 patients received bevacizumab only in a phase Ib trial [59].